| Identifier | Protein names | Gene names | Cross reference refseq | Length | Species |
| K9L7Z0 | MHC class I antigen; Fragment; | HLA-B; | NULL | 181 | human |
| R9Y3Y7 | Cytochrome b; | CYTB; | NULL | 380 | human |
| V9HWE0 | Annexin; | HEL-S-7; | NP_001145.1; | 320 | human |
| R9RUZ6 | Coiled-coil domain containing 28A/interleukin-22 receptor subunit alpha-2 fusion variant 2; Fragment; | CCDC28A; IL22RA2 fusion; | NULL | 191 | human |
| V9HWF4 | Phosphoglycerate kinase; EC 2.7.2.3; | HEL-S-68p; | NP_000282.1; | 417 | human |
| R9QG91 | Signal transducer and activator of transcription; | STAT2; | NULL | 851 | human |
| V9HWE7 | Epididymis secretory protein Li 19; | HEL-S-19; | NP_000145.1; | 392 | human |
| L0ES73 | Tumor suppressor p53; Fragment; | TP53; | NULL | 100 | human |
| V9J3S1 | Cytochrome c oxidase subunit 2; | COX2; | NULL | 227 | human |
| L0BXI1 | MHC class I antigen; Fragment; | HLA-B; | NULL | 181 | human |
| V9HWK1 | Triosephosphate isomerase; EC 5.3.1.1; | HEL-S-49; | NP_000356.1; | 249 | human |
| V9JAP4 | Cytochrome c oxidase subunit 1; EC 1.9.3.1; | NULL | NULL | 513 | human |
| V9J978 | Cytochrome c oxidase subunit 1; EC 1.9.3.1; | NULL | NULL | 513 | human |
| V9QAW3 | Melanocyte-stimulating hormone receptor; MSH-R; Melanocortin receptor 1; | MC1R; | NULL | 317 | human |
| V9N336 | MHC class II antigen; Fragment; | HLA-DRB1; | NULL | 89 | human |
| V9K5S5 | NADH-ubiquinone oxidoreductase chain 1; EC 1.6.5.3; | ND1; | NULL | 318 | human |
| V9HWG2 | Epididymis luminal protein 30; | HEL30; | NP_057058.2; | 319 | human |
| W0C540 | Cytochrome b; | CYTB; | NULL | 380 | human |
| V9JTH3 | NADH-ubiquinone oxidoreductase chain 2; EC 1.6.5.3; | ND2; | NULL | 347 | human |
| V9N9T2 | NADH-ubiquinone oxidoreductase chain 4; EC 1.6.5.3; | ND4; | NULL | 459 | human |
UrgentMab™: Thinking is cheap. Test your ideas, fast and furious. |
 |
|
Custom monoclonal antibody in one month. As low as $200-300 per antigen. |
|
A product of Absolution |
|
SEAL™: Today's out-of-reach protein targets made accessible. |
|
|
Same budget, 5-10 times more antibodying SEAL your protein. Successes too. |
|
A product of Absolution |
|
PETAL™: Fast and high throughput antibody discover platform. |
 |
|
Deliver customized antibody in two weeks at price of category antibody Proteome-scale antibody discovery for any organism or proteome Biomarker discovery for biological processes or human diseases |
|
A product of Absolution |
|
AbFocus™: Target all the modification sites of your protein, affordably. |
|
|
Test them with a panel of AbFocus antibodies It is so affordable that you can focus on testing, not guessing |
|
A product of Absolution |
Mabome™: Catch the antibody gold rush.? Lead the next omics revolution. |
|
|
First-ever antibody proteomics technology. High quality monoclonal antibodies for your favorite proteome. As low as $19/monoclonal antibody |
|
A product of Absolution |
AbTarget™: Performing antibody for your proteome.? Guaranteed |
|
|
Fast, efficient monoclonal antibody development for proteins in a proteome Pay for successful antibodies only |
|
A product of Absolution |
AbProfile™: Discover an array of unbiased differences.? Proteome-scale |
|
|
50,000 monoclonal antibodies on an array.100 times more content. Differential profiling thousands of cell surface receptorsand plasma proteins |
|
A product of Absolution |
|
SMAL™:?All big things have a SMAL beginning. |
|
|
High success rate for mAb generation Deliver a panel of high affinity mAbs Flexible and optional fee structure for minimizing risks |
|
A product of Absolution |
AbX™: X=anything.? Find your antibody within |
|
|
currently 7species.?200,000 mAbs.70,000 proteins 3 new organisms are being AbXed/day Pre-made anti-peptide mAbs against all proteins in nature. |
|
A product of AbStore |
AbStop™: The last stop of antibody development. The most successful stop. |
|
|
Pre-designed antibody packages against high value targets The most aggressive and comprehensive protein targeting Best for diagnostics and therapeutic antibody development |
|
A product of AbStore |